Nordic Science Investments

Solid IO is a biotechnology company specializing in organ-on-chip technology for oncology. It replicates the tumor microenvironment to provide real-time, patient-specific insights, enabling clinicians to make precise treatment decisions and accelerating immuno-oncology drug development.

Phenaros Pharmaceuticals is a Swedish spin-off drug discovery company from Uppsala University. We employ phenomics (large-scale cell morphological profiling) in conjunction with automation and AI to discover and repurpose medications for uncommon diseases. Aside from developing an in-house drug discovery pipeline, we also form collaborations to provide access to our discovery platform.

Acouspin is a technology company that specializes in AI-driven, ultrasonic-enhanced systems for efficient and flexible nanofiber production. Their innovative solution enables manufacturers to achieve precision in nanofiber production without requiring specific expertise. The technology addresses common challenges such as needle clogs, allows real-time adjustments to fiber diameters, and simplifies the manufacturing process, making it more accessible and efficient. This transformation opens up new possibilities for large-scale applications across various industries.

PrecisionPhage, based in Jyvaskyla, Finland, is a biotechnology company focused on bacteriophage technologies. It provides an online phage genome analysis tool and services including bioinformatic analyses, bacteriophage licensing, and laboratory services. These offerings enable healthcare firms to perform genome assembly, analysis, and comparison, as well as facilitate drug development research.

NADMED specializes in advanced technology for measuring nicotinamide adenine dinucleotide (NAD) and glutathione levels within biological samples. The company has developed a unique metabolite extraction system that allows for the measurement of all four types of NAD through a nondestructive extraction process combined with colorimetric quantification. This innovative approach has been utilized in research involving human and animal samples, including cells, liver, brain, muscle, and blood. By providing measuring kits and laboratory services, NADMED enables medical professionals and researchers to effectively assess NAD metabolism, supporting both clinical and research applications.

RNatives is a biotechnology company that specializes in developing RNA-based therapies, with a particular emphasis on RNA activation to address cardiovascular diseases. The company utilizes innovative approaches to modulate gene expression, specifically targeting the VEGFA gene to enhance its activity. RNatives is focused on treating conditions such as myocardial ischemia and peripheral artery disease by up-regulating the endogenous VEGFA gene through small RNA molecules. With a commitment to rigorous research and development, RNatives aims to create novel therapeutic options for patients with unmet medical needs, driven by a team of skilled professionals dedicated to advancing the field of biotechnology and improving patient outcomes.

AIATELLA is a healthcare technology company that specializes in cardiovascular diagnostics. It leverages artificial intelligence to automate the quantification, detection, and interpretation of medical images across various imaging modalities. By doing so, AIATELLA enhances efficiency, ensures standardized analysis, and facilitates precision medicine. This addresses global challenges such as radiologist shortages and the increasing burden of cardiovascular diseases.

Perfat Technologies is a health-focused technology company that specializes in the development of fat-management applications using healthy vegetable oils. The company employs advanced oleogel and ultrasound technologies to create plant-based fat alternatives, enhancing the functional properties of oils such as rapeseed and sunflower oil. By optimizing bioprocesses through its software, Perfat Technologies aims to accelerate research and development, reduce production costs, and improve sustainability in food production. This innovative approach broadens the use of healthy oils, making them more accessible for consumers while promoting better dietary choices.

RNatives is a biotechnology company that specializes in developing RNA-based therapies, with a particular emphasis on RNA activation to address cardiovascular diseases. The company utilizes innovative approaches to modulate gene expression, specifically targeting the VEGFA gene to enhance its activity. RNatives is focused on treating conditions such as myocardial ischemia and peripheral artery disease by up-regulating the endogenous VEGFA gene through small RNA molecules. With a commitment to rigorous research and development, RNatives aims to create novel therapeutic options for patients with unmet medical needs, driven by a team of skilled professionals dedicated to advancing the field of biotechnology and improving patient outcomes.